Mark Cuban's pharmacy, Cost Plus Drugs, is expected to be profitable in 2023, Forbes reported Sept. 26.
Mr. Cuban says the company has more than a million customers with roughly a 10 percent growth rate each week. Although no official revenue reports have been released, Forbes estimates Cost Plus has made at least $25 million in sales during the first nine months.
Cost Plus is expected to manufacture its own medications in a $11 million manufacturing facility in Dallas. The facility is expected to open in November and is an all-robotic plant designed to produce any drugs the company cannot source from other manufactures.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.